Off-label use of plenty of immunomodulatory drugs emerged, targeting cytokines involved in COVID-19 acute respiratory distress syndrome (ARDS), where high IL-6 levels have a prominent role (4). This evidence concerns the gene IL6 and acute respiratory distress syndrome.